Biological & operational considerations for iPSC-derived cell production

Cell & Gene Therapy Insights 2023; 9(11), 1493–1501

DOI: 10.18609/cgti.2023.196

Published: 20 December 2023
Expert Roundtable
A Mogen, A Fernandez-Perez, J Wang et al.

While cell therapies offer great promise, questions remain on the most effective tools and processes for transitioning from the lab bench into the production suite. In this roundtable discussion, four experts discuss considerations and challenges for scale-up of induced pluripotent stem cells. Methods and solutions for scaling production will be discussed, including biological and operational process optimizations.

Austin Mogen is a Field Application Scientist Manager for Western United States and Latin America at Corning Life Sciences. He gained industry experience as a Senior Scientist in upstream process development, and as a Manufacturing Supervisor for viral vector manufacturing. Since joining Corning, he has worked with academic researchers and process development groups, optimizing cell culture assays, and cellular scale-up conditions for viral production, cellular therapeutics, and biologics.

Antonio Fernandez-Perez is a Field Application Scientist at Corning Life Sciences. In previous roles, he worked on process development for iPSC-derived cellular immunotherapies for patients with cancer and autoimmune disorders. Antonio now works with academic researchers, biopharma companies, and advanced therapy manufacturers to optimize cell culture assays and cellular scale-up conditions using Corning technologies.

Jiwu Wang is the Founder and CEO of Allele Biotech, an early developer of RNAi, and the first market provider of shRNA reagents. His team constructed the field-leading fluorescent proteins mNeonGreen and mMaple, and he co-invented Allele’s mRNA reprogramming method, and established full GMP operations for generating and banking mRNA-induced pluripotent stem cells. He also founded the Scintillon Institute, which conducts research in bioengineering, neuroscience and behavior, immunology, and aging.

Andrew Chammas is a Process Development Scientist at Allele Biotech with an extensive background in iPSC-related workflows for cell therapy. He has played pivotal roles in innovating Allele’s core mRNA-based technology and adapting it to GMP standards. Currently, he manages iPSC-related pre-clinical process development efforts, focusing on the safe and efficient production of iPSC-derived therapies.